Lab In The News
Spotlight on Wistar COVID-19 Researchers: Luis Montaner, D.V.M., D.Phil., & Joseph Salvino, Ph.D.
Dr. Luis Montaner is an HIV expert focused on finding new ways to boost the natural function of the immune system to combat infection or viral-associated disease. Dr. Joseph Salvino is a medicinal chemist and an expert in drug discovery and identification of novel small molecule lead compounds. The...
The Salvino Laboratory
Salvino’s research is directed at drug discovery and development. His laboratory focuses on early drug discovery and small molecule tool compounds for in vivo target validation to confirm the pharmacological relevance and “drugability” of a therapeutic target. His lab’s work in medicinal chemistry optimization is focused on the design and creation of new chemical analogs to understand structure activity relationships (SAR) critical for optimizing potency and in vivo efficacy for a lead series. This effort is important to help identify a potential preclinical drug candidate or future therapeutic agent against a new biological target.
Salvino is the Scientific Director of the Molecular Screening & Protein Expression Shared Resource which closely aligns screening capabilities for lead optimization and hit-to-lead activities that are ongoing in his laboratory.
Current projects include compounds blocking HIV and other antivirals, glutamate transporter (EAAT2) stimulators, ACSS2 Inhibitors, Proteolysis Targeting Chimeras (PROTACs) with a focus on CDK6, Mdm2, and Tert degraders, small molecules targeting protein-protein interactions, chemical probes for assay development, and cancer targeting and gram-negative bacteria targeting pro-drugs.
Adi Narayana Reddy Poli, Ph.D.
Jitendra Gour, Ph.D.
Irfan Khan, Ph.D.
Nitesh Nandwana, Ph.D.
UPenn Capstone Masters in Chemistry Students
Porazzi, P., Dominici, M.D., Salvino, J., Calabretta, B. “Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.” Genes (Basel). 2021 Aug 29;12(9):1355. doi: 10.3390/genes12091355.
Walden, M., Tian, L., Ross, R.L., Sykora, U.M., Byrne, D.P., Hesketh, E.L., Masandi, S.K., Cassel, J., George, R., Ault, J.R., Oualid, F.E., et al. “Metabolic Control of Brisc-shmt2 Assembly Regulates Immune Signalling.” Nature. 2019 Jun;570(7760):194-199. doi: 10.1038/s41586-019-1232-1. Epub 2019 May 29.
Miller, K.D., Pniewski, K., Perry, C.E., Papp, S.B., Shaffer, J.D., Velasco-Silva, J.N., Casciano, J.C., Aramburu, T.M., Srikanth, Y.V.V., Cassel, J., et al. “Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth.” Cancer Res. 2021 Mar 1;81(5):1252-1264. doi: 10.1158/0008-5472.CAN-20-1847. Epub 2021 Jan 7.
Dominici, M.D., Porazzi, P., Xiao, Y., Chao, A., Tang, H., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L.F., et al. “Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.” Blood. 2020 Apr 30;135(18):1560-1573. doi: 10.1182/blood.2019003604.
Tikhmyanova, N., Paparoidamis, N., Romero-Masters, J., Feng, X., Mohammed, F.S., Narayana Reddy, P.A., Kenney, S.C., Lieberman, P.M., Salvino, J.M. “Development of a Novel Inducer for Ebv Lytic Therapy.” Bioorg Med Chem Lett. 2019 Aug 15;29(16):2259-2264. doi: 10.1016/j.bmcl.2019.06.034. Epub 2019 Jun 22.